Hereditary Angioedema on Long-Term Prophylaxis: A Narrative Review of Attack Prevention and What Treatment Changes for Daily Life
DOI:
https://doi.org/10.5281/zenodo.22237544Keywords:
Hereditary Angioedema, Long-Term Prophylaxis, Plasma Kallikrein Inhibition;, Quality of LifeAbstract
Hereditary angioedema produces swelling that is disfiguring, painful and, when it involves the larynx, occasionally fatal. Until
recently the disease was managed by treating attacks. It can now be managed by largely preventing them, which changes what
the condition is rather than merely how it is treated. Objectives: To review the published evidence on long-term prophylaxis in hereditary angioedema: how far attack rates fall, how many patients become attack-free, how the available agents compare, and what remains unaddressed once attacks stop. Material and Methods: Narrative review of randomised trials, open-label extensions, real-world cohorts, network meta-analysis and international guidance indexed in PubMed and the major allergy and immunology journals. No new patient data were generated; every estimate quoted is one published by the original investigators. Results: In the pivotal randomised trial, a monoclonal plasma kallikrein inhibitor reduced attack rates by approximately 87 per cent against placebo, with around 44 per cent of patients attack-free over 26 weeks and 77 per cent attack-free for 16 weeks once
steady state was reached. Secondary outcomes fell correspondingly: attacks requiring acute treatment by 74 to 87 per cent and
moderate or severe attacks by 71 to 83 per cent. In the open-label extension of 212 patients followed for a mean of 29.6 months,
attack rate fell 87.4 per cent overall, 37.3 per cent were attack-free throughout, and 97.7 per cent of days were attack-free.
Conclusion: Prophylaxis converts a disease of recurrent emergencies into one of occasional events for most patients, and the
open-label data suggest the effect is durable. The remaining questions are about access, cost and the smaller group who continue
to have attacks, none of which the efficacy trials address. Abbreviations: C1-INH – C1 Inhibitor, HAE – Hereditary Angioedema, LTP – Long-Term Prophylaxis, NMA – Network Meta-Analysis, OLE – Open-Label Extension, q2wks – Every Two Weeks, TEAE – Treatment-Emergent Adverse Event.
References
Zuraw BL. "Hereditary angioedema". N Engl J Med 359(2008):1027-1036.
Busse PJ, Christiansen SC. "Hereditary angioedema". N Engl J Med 382(2020):1136-1148.
Bork K, Hardt J, Witzke G. "Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency". J Allergy Clin Immunol 130(2012):692-697.
Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, et al. "Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States". Ann Allergy Asthma Immunol 124(2020):600-607.
Zanichelli A, Magerl M, Longhurst H, Fabien V, Maurer M. "Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe". Allergy Asthma Clin Immunol 9(2013):29.
Bork K, Staubach P, Eckardt AJ, Hardt J. "Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency". Am J Gastroenterol 101(2006):619-627.
Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. "The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression". Allergy Asthma Proc 31(2010):407-414.
Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygoren-Pursun E, et al. "The international WAO/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update". Allergy 77(2022):1961-1990.
Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. "US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema". J Allergy Clin Immunol Pract 9(2021):132-150.
Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, et al. "Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial". JAMA 320(2018):2108-2121.
Longhurst H, Cicardi M, Craig T, Bork K, Grattan C, Baker J, et al. "Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor". N Engl J Med 376(2017):1131-1140.
Zuraw B, Lumry WR, Johnston DT, Aygoren-Pursun E, Banerji A, Bernstein JA, et al. "Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial". J Allergy Clin Immunol 148(2021):164-172.
Riedl MA, Maurer M, Bernstein JA, Banerji A, Longhurst HJ, Li HH, et al. "Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks". Allergy 75(2020):2879-2887.
Lumry WR, Weller K, Magerl M, Banerji A, Longhurst HJ, Riedl MA, et al. "Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study". Allergy 76(2021):1188-1198.
Banerji A, Bernstein JA, Johnston DT, Lumry WR, Magerl M, Maurer M, et al. "Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study". Allergy 77(2022):979-990.
Maurer M, Lumry WR, Li HH, Aygoren-Pursun E, Bernstein JA, Craig T, et al. "Long-term prophylaxis with lanadelumab: patterns of attack-free intervals in the HELP open-label extension". Allergy 77(2022):1-11.
Bernstein JA, Maurer M, Magerl M, Banerji A, Riedl MA, Lumry WR, et al. "Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents". Ann Allergy Asthma Immunol 133(2024):1-9.
Wedner HJ, Aygoren-Pursun E, Bernstein J, Craig T, Gower R, Jacobs JS, et al. "Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2)". J Allergy Clin Immunol Pract 9(2021):2305-2314.
Bernstein JA, Tomita D, Machnig T, Juethner S, Anderson J. "Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema". J Comp Eff Res 12(2023):e220188.
Riedl MA, Craig TJ, Banerji A, Aygoren-Pursun E, Bernstein JA, Lumry WR, et al. "Sustained effectiveness, tolerability, and safety of long-term prophylaxis with lanadelumab in hereditary angioedema: the prospective, phase 4, noninterventional EMPOWER real-world study". Adv Ther (2025).
Bork K, Bygum A, Hardt J. "Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients". Ann Allergy Asthma Immunol 100(2008):153-161.
Princic N, Evans KA, Shah CH, Sing K, Juethner S, Schultz BG. "Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis". J Comp Eff Res 14(2025):e240205.
Craig T, Lumry W, Riedl MA, Bernstein JA, Banerji A, Maurer M, et al. "Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER/ENABLE". Pediatr Allergy Immunol (2025).
Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. "Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema". N Engl J Med 363(2010):532-541.
Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, et al. "Ecallantide for the treatment of acute attacks in hereditary angioedema". N Engl J Med 363(2010):523-531.
Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, et al. "Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks". J Allergy Clin Immunol 124(2009):801-808.
Aygoren-Pursun E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Wait S, et al. "Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe". Orphanet J Rare Dis 9(2014):99.
Banerji A, Busse P, Christiansen SC, Li H, Lumry W, Davis-Lorton M, et al. "Current state of hereditary angioedema management: a patient survey". Allergy Asthma Proc 36(2015):213-217.
Longhurst HJ, Bork K. "Hereditary angioedema: an update on causes, manifestations and treatment". Br J Hosp Med 80(2019):391-398.
Maurer M, Magerl M. "Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives". J Dtsch Dermatol Ges 9(2011):99-107.
Nordenfelt P, Nilsson M, Bjorkander J, Mallbris L, Lindfors A, Wahlgren CF. "Hereditary angioedema in Swedish adults: report from the national cohort". Acta Derm Venereol 96(2016):540-545.
Christiansen SC, Zuraw BL. "Treatment of hereditary angioedema: established and newer therapies". Curr Opin Allergy Clin Immunol 15(2015):352-358.
Riedl MA, Banerji A, Gower R. "Current medical management of hereditary angioedema: follow-up survey of US physicians". Ann Allergy Asthma Immunol 126(2021):264-272.
Lumry WR, Zuraw B, Cicardi M, Craig T, Anderson J, Banerji A, et al. "Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks". Orphanet J Rare Dis 16(2021):86.
Bygum A, Aygoren-Pursun E, Beusterien K, Hautamaki E, Sisic Z, Wait S, et al. "Burden of illness in hereditary angioedema: a conceptual model". Acta Derm Venereol 95(2015):706-710.
